Dr Adi Suwandi

Adi Suwandi is a medicinal chemist specialising in the design and synthesis of small molecules for drug discovery, with a particular interest in applying computational and AI-driven approaches to accelerate molecular design. He completed his PhD at Monash University, where his research focused on the design and synthesis of novel pyrophosphate bioisosteres as KAT6A inhibitors. His work combined structure-based drug design with computational modelling to guide compound synthesis and optimisation, providing a strong foundation in medicinal chemistry, chemical synthesis, and the development of biologically active small molecules.

Through his research and training, Adi has developed expertise in integrating computational methods with traditional medicinal chemistry workflows to improve the biological and drug-like properties of lead compounds. His interests span molecular design, hit-to-lead optimisation, and the application of emerging technologies to enhance the efficiency and success of drug discovery programs.

Adi currently works as a translational Medicinal Chemist with the Australian Translational Medicinal Chemistry Facility (ATMCF), in a MedChem Australia research program. In this role, he combines in silico and AI-enabled approaches with contemporary medicinal chemistry to advance small-molecule drug discovery projects towards therapeutic and commercial outcomes. His work bridges early-stage discovery research and translational development, helping to progress promising compounds towards industry-ready assets with clinical and commercial potential.